Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Price Target at $21.57

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $21.57.

A number of analysts have weighed in on the stock. Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Finally, Cantor Fitzgerald raised shares of Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, January 29th.

Insider Activity

In other news, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the transaction, the chief executive officer now directly owns 222,060 shares of the company’s stock, valued at $1,745,391.60. The trade was a 21.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the transaction, the chief financial officer now directly owns 51,361 shares in the company, valued at $403,697.46. The trade was a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 85,773 shares of company stock valued at $674,176 in the last ninety days. 2.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Woodline Partners LP grew its position in Zevra Therapeutics by 2.2% in the 4th quarter. Woodline Partners LP now owns 4,139,593 shares of the company’s stock valued at $34,524,000 after buying an additional 90,940 shares during the last quarter. Velan Capital Investment Management LP grew its position in Zevra Therapeutics by 50.0% in the 4th quarter. Velan Capital Investment Management LP now owns 300,000 shares of the company’s stock valued at $2,502,000 after buying an additional 100,000 shares during the last quarter. Squarepoint Ops LLC grew its position in Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after buying an additional 4,384 shares during the last quarter. ProShare Advisors LLC purchased a new position in Zevra Therapeutics in the 4th quarter valued at $145,000. Finally, Millennium Management LLC grew its position in Zevra Therapeutics by 138.2% in the 4th quarter. Millennium Management LLC now owns 233,132 shares of the company’s stock valued at $1,944,000 after buying an additional 135,246 shares during the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Stock Down 2.8 %

Shares of Zevra Therapeutics stock opened at $7.73 on Friday. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76. The company has a 50 day moving average of $8.16 and a 200 day moving average of $8.09. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $412.63 million, a P/E ratio of -3.92 and a beta of 2.00.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.